ClinicalTrials.Veeva

Menu

MOWOOT Device Treatment for Adults with Chronic Constipation (MOTACC)

U

usMIMA

Status

Enrolling

Conditions

Constipation; Neurogenic
Constipation - Functional
Constipation Chronic Idiopathic
Constipation
Constipation-predominant Irritable Bowel Syndrome

Treatments

Device: Standard of care with Trans-Anal Irrigation
Device: Intermittent Colonic Exoperistalsis with MOWOOT device

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT04666155
MOW-06-2023

Details and patient eligibility

About

The primary objective is to compare the effectiveness of the experimental Intermittent Colonic Exoperistalsis (ICE) treatment with MOWOOT, with the active control of trans-anal irrigation (TAI) as standard-of-care. The secondary objectives are to further compare the ICE treatment with MOWOOT to the TAI standard-of-care clinically and economically.

Full description

The RCT will assess clinical effectiveness by means of quantitative and qualitative variables, and the cost effectiveness by means of economic outcomes.

Enrollment

86 estimated patients

Sex

All

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Any gender 18 years or older
  2. Symptoms meeting the American College of Gastroenterology definition of chronic constipation: unsatisfactory defaecation characterized by infrequent stool, difficult stool passage or both for at least previous 3 months
  3. Bothered by their constipation
  4. PAC-QOL ≥1.8
  5. Using TAI for at least 3 months
  6. Able to undertake the treatment with TAI or with the device themselves or with a carer willing to do it
  7. Able to understand the study requirements
  8. Able to understand written and spoken English (due to questionnaire validity)
  9. Able and willing to provide written informed consent to participate

Exclusion criteria

Disease phenotype exclusion criteria:

  1. Irritable Bowel Syndrome with Diarrhoea (IBS-D) or alternating constipation and diarrhoea (IBSmix): (not due to laxative use)

  2. Inflammatory Bowel Disease (IBD)

    Device-related exclusion criteria:

  3. Abdominal perimeter ≤65cm or ≥130cm

  4. Unable to independently use the MOWOOT or TAI technology, unless a carer is available daily to assist

    Other medical conditions, medications and contraindications:

  5. Previous large bowel resection

  6. The presence of a stoma

  7. External rectal prolapse

  8. Active anorexia or bulimia

  9. Active abdominal cancer

  10. Large inguinal or umbilical hernia

  11. Recent abdominal scars, abdominal wounds or skin disorders that may make abdominal massage uncomfortable

  12. Pregnancy or attempt to become pregnant in the next 6 months

  13. Use of strong opioids*

  14. Use of antidepressants, bladder stabilisers or any other medication inducing, or treating, constipation unless used at a stable dose for at least 4 weeks before Screening Visit (this excludes laxatives which may be used as required up to three days before the screening visit)

  15. Subjects already undertaking or have undertaken abdominal massage unless they underwent a previous washout period of at least 2 months

  16. Participation in another parallel interventional clinical trial or less than 2 months from participation in a previous interventional clinical trial

  17. Planned surgery for constipation if it might be within trial dates

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

86 participants in 2 patient groups

Intermittent Colon Exoperistalsis (ICE)
Experimental group
Description:
Intermittent Colon Exoperistalsis (ICE) Treatment with Mowoot device. 20min daily for 12 weeks
Treatment:
Device: Intermittent Colonic Exoperistalsis with MOWOOT device
Device: Standard of care with Trans-Anal Irrigation
Standard-of-care with Trans-anal Irrigation (Soc TAI)
Active Comparator group
Description:
Standard-of-care with Trans-anal Irrigation (Soc TAI) for chronic constipation for 12 weeks.
Treatment:
Device: Standard of care with Trans-Anal Irrigation

Trial contacts and locations

1

Loading...

Central trial contact

Immaculada Herrero, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems